Could someone comment stadistics for Teva, Milan, Actavis(watson)
Just dont find a logical reason for Teva to lag behind its peers by such a big PS difference . Uncomprenhensible. The only very obvious difference is that Teva is headquatered in Israel.But i still cant believe this is slowing Teva so much. imao.
MAX and other honorable hebrew speaking board members perhaps you can acces local news that we cant.
Could you offer a clue for the rest of us ? if you have of course?
2) Greedy BOD that increases its (and its chairman's) benefits by huge ratios at a time that Teva shares act like siht for a very long time and shareholders are losing their "behind" with their Teva investments.
3) A company in transition - will they make it?
4) According to the Street - Lower cash flow margin YOY.
5) A phenomena that is feeding itself - stock price goes down, more and more investors are throwing in the towel and are getting out of the stock.
One other key point Max. No definitive plan for a drug launch to recapture losses of Copaxone competition. Yes, they've offered the idea of cost cutting measures to somewhat offset the loss, but investors are interested in drug launches, period.